News >

Tempero Spotlights Frontline Treatment Options in Pancreatic Cancer

Caroline Seymour
Published: Tuesday, Apr 10, 2018

Margaret A. Tempero, MD

Margaret A. Tempero, MD
The results of a clinical trial exploring pegvorhyaluronidase alfa (PEGPH20) in combination with nab-paclitaxel (Abraxane) and gemcitabine could impact practice for physicians who treat patients with pancreatic cancer, says Margaret A. Tempero, MD.

Additionally, physicians are seeking to manage adverse events (AEs) associated with chemotherapy agents like FOLFIRINOX, gemcitabine, and nab-paclitaxel. Window-of-opportunity trials, or trials that explore developing agents in patients who responded to but failed to standard therapy, are critical to this effort, Tempero adds.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to PatientOct 31, 20191.5
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Publication Bottom Border
Border Publication